BAYRY
Bayer AG Spons ADR$13.99 +0.62 (+4.64%)
Oct 30 4:00 PM ET · prev $13.37
Median target
🔒 Subscribers only
1 year
+80.5%
from $7.75 · Oct 31
30 days
+3.6%
from $13.50
52-week range
$7.56–15.19
−8% from high · low Nov 3
Avg volume 20D
610.0K
shares / day
Short interest
313.8K
−24.5%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Congress trades
9
disclosed
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Aug 10 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- E Aug 11 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- X Aug 14 Short interest jumps 26.6% to 661.8K
- E Aug 25 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- X Aug 31 Short interest falls 80.8% to 127.3K
- X Sep 15 Short interest jumps 183.4% to 360.8K
- E Sep 23 Trial readout: Results Pending: BAY2599023 (DTX201) (Phase 2), Completed…
- E Oct 23 Trial readout: Results Pending: BAY2599023 (DTX201) (Phase 2), Completed…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- Short sellersCOVERING
Short interest −24.5% to 313.8K shares. 1.0 days to cover.
- TrendRANGE
4% above its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| First Command Advisory Services, Inc. | DOUBLED | $40.7K |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | $34.8K |
| KAHN BROTHERS GROUP INC | ADD | $39.6M |
| GREAT LAKES ADVISORS, LLC | ADD | $804.4K |
| RHUMBLINE ADVISERS | ADD | $443.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 28, 2026 Event
HSR Early Termination: Grunenthal Pharma GmbH & Co. KG; Bayer AG
The FTC granted early termination of the HSR Act waiting period for a transaction involving Grunenth
Oct 23, 2026 Clinical trial readout
Results Pending: BAY2599023 (DTX201) (Phase 2), Completed 38d ago
Trial: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment
Jun 30, 2026 Inst.
First Command Advisory Services, · DOUBLED
2,971 shares ($40.7K)
May 29, 2026 Congress
Michael McCaul sell
$15,001 - $50,000 · House
May 12, 2026 Congress
Michael McCaul sell
$15,001 - $50,000 · House
Mar 31, 2026 Inst.
PNC FINANCIAL SERVICES GROUP, · DOUBLED
3,030 shares ($34.8K)
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Congressional trades
BAYRY trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 9 sells
DateMemberType AmountDisclosed
May 29, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $15K–$50K Jun 10, 2026 +12d
May 12, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $15K–$50K Jun 10, 2026 +29d
Apr 23, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $15K–$50K May 4, 2026 +11d
Apr 15, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K May 4, 2026 +19d
Apr 8, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K May 4, 2026 +26d
Mar 17, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K Apr 8, 2026 +22d
Feb 17, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K Mar 12, 2026 +23d
Feb 6, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K Mar 12, 2026 +34d
Feb 5, 2026 Michael McCaulRHouse Spouse account · Bayer AG SELL $1K–$15K Mar 12, 2026 +35d
Short side
FINRA· Oct 15, 2026313,781
shares short
-24.5%
vs prior settlement
1.0
days to cover
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 28, 2026
Enforcement
HSR Early Termination: Grunenthal Pharma GmbH & Co. KG; Bayer AG
The FTC granted early termination of the HSR Act waiting period for a transaction involving Grunenthal Pharma GmbH & Co. KG; Bayer AG.
Oct 27, 2026
Clinical Trial
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Phase 3 · COMPLETED
Oct 23, 2026
Trial readout
Results Pending: BAY2599023 (DTX201) (Phase 2), Completed 38d ago
Trial: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That…
Oct 8, 2026
Clinical Trial
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
Phase 3 · COMPLETED
Oct 5, 2026
Clinical Trial
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Phase 3 · COMPLETED